Incidence and Nature of Adverse Events Associated with Intravenous Therapy: A Multi-Site Observational Study
The founding paper of Issue One is the American IV Association’s Multi-Site Observational Study on the Incidence and Nature of Adverse Events Associated with Intravenous Therapy. It is publishing as the founding paper of Issue One of the IV Therapy Journal.
What the study set out to measure
The study was designed to answer a basic question the field has never had a shared answer to: when IV therapy is delivered in outpatient clinics, what adverse events occur, of what types, and at what severity?
Conducted across multiple clinics over a 30-day collection period, the study recorded adverse events associated with intravenous therapy and classified each event by type and by severity on a grading scale adapted from the CTCAE criteria used in oncology. That design — many sites, one shared definition of an event, one shared severity scale — is what turns separate clinics’ day-to-day experience into a dataset the whole field can use.
Why it matters
Safety claims in IV therapy have run ahead of safety data. Without a multi-site record of adverse events, clinicians cannot benchmark their own practice, patients cannot weigh real-world experience, and the field cannot show its work. A foundational safety dataset — collected prospectively, graded consistently, and published with its methods open to scrutiny — is the starting point the journal was founded to provide, and the standard its author guidelines ask every future safety paper to meet.
Status
The manuscript is in preparation. It is publishing as the founding paper of Issue One — watch the journal home page for the Issue One announcement.